Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Yue Shentu"'
Autor:
Minjie Luo, Xiangfeng Cui, David Fredman, Anthony J Brookes, Marco A Azaro, Danielle M Greenawalt, Guohong Hu, Hui-Yun Wang, Irina V Tereshchenko, Yong Lin, Yue Shentu, Richeng Gao, Li Shen, Honghua Li
Publikováno v:
PLoS ONE, Vol 4, Iss 4, p e5236 (2009)
Copy number variants (CNVs) occupy a significant portion of the human genome and may have important roles in meiotic recombination, human genome evolution and gene expression. Many genetic diseases may be underlain by CNVs. However, because of the pr
Externí odkaz:
https://doaj.org/article/3cba0054531744a9851f6b3814dc43bd
Autor:
Yi Liu, Miao Yang, Siyoen Kil, Jiang Li, Shoubhik Mondal, Yue Shentu, Hong Tian, Liwei Wang, Godwin Yung
An important goal of precision medicine is to identify biomarkers that are predictive, and tailor the treatment according to the biomarker levels of individual patients. Differentiating prognostic versus predictive biomarkers impacts important decisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17491f39a09a3af176594660a54d31c
Publikováno v:
Statistics in Biopharmaceutical Research. 14:523-531
In randomized clinical trials, there has been an increasing interest in identifying subgroups with heterogeneous responses to study treatment based on baseline patient characteristics. Even though the benefit risk assessment of any patient population
Autor:
Salma K. Jabbour, Byoung Chul Cho, Emilio Bria, Terufumi Kato, Jaishree Bhosle, Justin F. Gainor, Noemi Reguart, Luhua Wang, Daniel Morgensztern, Yue Shentu, Sung Jin Kim, Fabricio Souza, Martin Reck
Publikováno v:
Clinical lung cancer. 23(6)
Concurrent chemoradiotherapy is a standard therapy for patients with stage III non-small-cell lung cancer (NSCLC). Durvalumab is an approved treatment option following concurrent chemoradiotherapy in the absence of disease progression. The multicente
Publikováno v:
Statistics in Medicine. 39:4133-4146
In randomized clinical trials with survival outcome, there has been an increasing interest in subgroup identification based on baseline genomic, proteomic markers or clinical characteristics. Some of the existing methods identify subgroups that benef
Autor:
Yue Shentu, Godwin Yung, Kaspar Rufibach, Steven Sun, Feng Liu, Oliver Sailer, Jonathan Siegel, Yi Liu, Rui Tang, Evgeny Degtyarev, Michelle Casey, Stefan Englert, Jiangxiu Zhou
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
–Coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and its broad applicability for future clinica
Autor:
Xin Li, Bohdana Ratitch, Hale Michael Don, Stefan Englert, Hui Quan, Peng-Liang Zhao, David Wright, Norman Bohidar, Olga Marchenko, Ming Zhou, Marcel Wolbers, Daniel Li, Christine Fletcher, R. Daniel Meyer, Thomas Liu, Wei Shen, Jyotirmoy Dey, Yue Shentu
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The COVID-19 pandemic has had and continues to have major impacts on planned and ongoing clinical trials. Its effects on trial data create multiple potential statistical issues. The scale of impact is unprecedented, but when viewed individually, many
Autor:
Emily Martin, Godwin Yung, Juliane Manitz, Mindy Mo, Rui Sammi Tang, Vincent Haddad, Kaspar Rufibach, Fei Jie, Hannes Buchner, Jyotirmoy Dey, Marie-Laure Casadebaig, Jiangxiu Zhou, Natalia Kan-Dobrosky, Yue Shentu, Viktoriya Stalbovskaya, Evgeny Degtyarev
Publikováno v:
Pharmaceutical statisticsREFERENCES. 21(1)
An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise defi
Autor:
Marcel Wolbers, Yue Shentu, Jianchang Lin, Kaspar Rufibach, Heinz Schmidli, Yi Liu, Devan V. Mehrotra, Satrajit Roychoudhury, Björn Bornkamp
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristics. Often, however, clinical questions also arise regarding the treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::631580e7f3988101e639180cf9d3f9fe
Publikováno v:
Statistics in Biosciences. 10:342-356
In some clinical development programs, there are potential biomarkers with promising but uncertain predictive effect, while the probability of success in the overall population cannot be readily dismissed. It is risky to focus only on the overall pop